Free Trial

Northwest Biotherapeutics Q1 2023 Earnings Report

Northwest Biotherapeutics logo
$0.26 +0.00 (+0.89%)
(As of 12/20/2024 05:55 PM ET)

Northwest Biotherapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Northwest Biotherapeutics Revenue Results

Actual Revenue
$0.88 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Northwest Biotherapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

$2 Trillion Disappears Because of Fed's Secretive New Move (Ad)

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Click here to see his new research now.

Northwest Biotherapeutics Earnings Headlines

Northwest Biotherapeutics: All Is Not Well With This One
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Behind the Bell: Arcutis Biotherapeutics
0K95.IL,0P0000AFQ5,0 (0K95.IL)
See More Northwest Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Northwest Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Northwest Biotherapeutics and other key companies, straight to your email.

About Northwest Biotherapeutics

Northwest Biotherapeutics (OTCMKTS:NWBO), a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

View Northwest Biotherapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings